Triple-negative breast cancer: treatment challenges and solutions
Guy Jérusalem(Centre Hospitalier Universitaire de Liège), Laurence Lousberg(Centre Hospitalier Chrétien), Hélène Schroeder(Centre Hospitalier Universitaire de Liège), Joëlle Collignon(Centre Hospitalier Universitaire de Liège)
Cited by 382
Related Papers
Cardio-Oncology Services: rationale, organization, and implementation
|European Heart Journal|2018|303
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
|The Lancet Oncology|2019|193
Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis
|JNCI Journal of the National Cancer Institute|2020|102
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
|Journal of Clinical Oncology|2023|100
Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies
|Therapeutic Advances in Medical Oncology|2016|40